PTN Palatin Technologies, Inc.

1.31-0.06 (-4.38%)
Close: June 18, 2019

1.330.02 (+1.53%)
Pre-market

Quote

Previous Close
$1.31
Day Range
$1.30-$1.42
52 Week Range
$0.59-$1.74
Volume
2,613,333
Avg Volume
3,174,642
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$266.01M
Enterprise Value (EV)
$246.48M
PE Ratio
-
EV/EBITDA
9.49
Price/Sales
-
Price/Book
9.87
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-
EBITDA
$25.98M
EPS, ttm
-$0.02
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
9/11/2019 (84 days)
Debt to Equity
23%
Debt
$18.47M
Cash
$38.00M
Net Debt
-

Performance

Beta
0.90
200 Day Moving Avg
$0.97
50 Day Moving Avg
$1.29
52 Week Change
49.78%
YTD Change
73.40%
1 Month Change
-11.61%
3 Month Change
38.04%
6 Month Change
92.44%
1 Year Change
49.78%
2 Year Change
184.16%
5 Year Change
8.70%

Share Count

Shares Outstanding
203.1M
Float
191.8M
Restricted Shares
11.2M
Restricted Shares, %
5.54%

Palatin Technologies, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Carl Spana

Website: http://www.palatin.com

Description: Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.

Employees: 19